Dacarbazine or Temozolomide

Phase 2Small molecule

TThe First Hospital of Jilin University

Dacarbazine or Temozolomide is one of 9 small molecule programs targeting Mucosal Melanoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mucosal MelanomaRecruiting

Mucosal MelanomaPhase 2

Recruiting

Competition

Competitive Landscape

8 competitors in Mucosal Melanoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

5 2

Opdivo

Bristol-Myers Squibb

Phase 2

4 3

Lenvima

Eisai

Phase 2

3 4

Yervoy

Bristol-Myers Squibb

Phase 2

2 5

Inlyta

PPrism Pharmaceuticals

Phase 2

1 6

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 8

Carilizumab and Apatinib

PPeking University Third Hospital

Phase 2

1 9

Dacarbazine or Temozolomide

TThe First Hospital of Jilin University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Recruiting

Mucosal Melanoma

NCT07400302

Clinical

Trials by Indication[1]

Mucosal Melanoma1 trial

A Randomized, Controlled, Multicenter Phase II Clinical Study Evaluating the Adjuvant Treatment of PD-L1-Positive, Resectable Mucosal Melanoma With Sintilimab Plus Chemotherapy Versus Chemotherapy Alone

Recruiting·TThe First Hospital of Jilin University·Phase 2·NCT07400302·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dacarbazine or Temozolomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dacarbazine or Temozolomide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dacarbazine or Temozolomide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Hospital of Jilin University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe First Hospital of Jilin University

Dacarbazine or Temozolomide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Mucosal Melanoma1 trial

References

Drug Info

Quick Facts

Related News